ArticleUpdates in surgery2026
Premedication with Lugol's solution in total thyroidectomy for graves' disease and toxic multinodular goiter: is it still indicated?
Article in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Novel triple-drug regimen for preoperative optimization in giant Graves' disease: a prospective efficacy and safety trial.Gland surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Premedication with Lugol's solution (LS) has traditionally been used to reduce the vascularization and friability of the thyroid gland before total thyroidectomy in patients with Graves' disease (GD) and toxic multinodular goiter (TMNG) with thyrotoxicosis and/or with undetectable serum TSH. However, the effectiveness and applicability of this treatment remain subjects of debate. This study aims to evaluate the surgical and postoperative outcomes in patients premedicated with LS compared to those who were not premedicated. Data from 100 patients who underwent total thyroidectomy for GD and TMNG at our center from 2014 to 2024 were analyzed. Patients were divided into two groups: Lugol+, premedicated with LS (n = 57), and Lugol-, not premedicated (n = 43). Variables analyzed included thyroid diameter, thyroid weight, operative time, postoperative hemorrhage, hypocalcemia, recurrent laryngeal nerve palsy, length of hospital stay, rate of reintervention for hemorrhage, intraoperative thyroid consistency. No statistically significant differences were found between the groups regarding postoperative hemorrhage (1.7% in Group Lugol+ vs. 2.3% in Group Lugol-), operative time (median: 95 vs. 85 min), immediate postoperative complications such as transient hypoparathyroidism (15.8% vs. 9.3%) and transient recurrent laryngeal nerve (RLN) palsy (3.5% vs. 2.3%), nor the other variables analyzed. Our data suggest that routine preoperative preparation with LS may not be mandatory. This study supports the thesis that patients with GD and TMNG who cannot be premedicated due to inability to obtain LS, insufficient time for preoperative preparation, or lesser compliance by patient, may still be eligible for surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.